Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy

Page view(s)
6
Checked on Nov 14, 2022
Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Title:
Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Other Titles:
Oncotarget
Publication Date:
29 December 2015
Citation:
Neo SH, Lew QJ, Koh SM, Zheng L, Bi X, Chao SH. Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy. Oncotarget. 2016;7(5):5483‐5494. doi:10.18632/oncotarget.6794
Abstract:
Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb) and is recently identified as a novel positive regulator of p53. We previously showed the basic region (BR) of HEXIM1 mediates the binding of HEXIM1 to a nucleolar protein, nucleophosmin (NPM), and can be ubiquitinated by human double minute 2 protein. Here we identify a cytotoxic peptide derived from the BR of HEXIM1. When fused with a cell-penetrating peptide, the HEXIM1 BR peptide triggers rapid cytotoxic effect independent of p53. Similarly, when the BR peptide is linked with a breast cancer cell targeting peptide, LTV, the LTV-BR fusion peptide exhibits specific killing of breast cancer cells, which is not observed with the commonly used cytotoxic peptide, KLA. Importantly, the BR peptide fails to enter cells by itself and does not induce any cytotoxic effects when it is not guided by any cell-penetrating or cancer targeting peptides. We showed that HEXIM1 BR peptide depolarizes mitochondrial membrane potential in a p53-dependent manner and its cell-killing activity is not suppressed by caspase inhibition. Furthermore, we observed an accumulation of the internalized BR peptide in the nucleoli of treated cells and an altered localization of NPM. These results illustrate a novel mechanism which the BR peptide induces cell death and can potentially be used as a novel therapeutic strategy against breast cancer.
License type:
http://creativecommons.org/licenses/by/4.0/
Funding Info:
This research / project is supported by Bioprocessing Technology Institute, A*STAR
Description:
ISSN:
1949-2553
Files uploaded: